NOV 16, 2021 8:36 AM PST

Psilocybin and Cannabis to Treat Anxiety and Addiction

WRITTEN BY: Kerry Charron

Johns Hopkins University’s Center for Psychedelic and Consciousness Research just received a $4.9 million grant to study how psychedelic treatment affects behavior, mood, cognition, brain function, and biological markers of health. This landmark grant will allow JHU researchers to conduct a multi-site -multi-year- study building on their previous research pointing to the effectiveness of psychedelic treatments for addiction and anxiety disorders.

Several earlier research studies highlighted the effectiveness of psilocybin in managing addiction and anxiety. JHU’s 2014 pilot study examined the role psilocybin played in smoking cessation. Participants engaged in 15 weeks of intensive therapy and journaling about smoking addiction triggers prior to receiving the psilocybin. In supported conditions with proper screening, preparation, monitoring, and follow up care, participants experienced a reduction of nicotine craving after taking moderate psilocybin doses. JHU researchers believe that psilocybin is effective because it is a non-addictive way to treat the root cause of addiction and not just the symptoms associated with nicotine withdrawal. Some study participants claim they have not had a cigarette since the psilocybin treatment for smoking cessation.

A 2016 study found that psilocybin alleviated the anxiety and depression experienced by cancer patients. Researchers noted patients sustained moderate to high improvements in mood for 6 months. JHU researchers believe that this efficacy is the result of psilocybin enabling “crosstalk” between different parts of the brain that helps minimize anxious thoughts.

The effects of psychedelics and cannabis are both under-researched, but they are gaining widespread attention for their medicinal potential. A recent research study on cannabis use for mood disorders suggests that cannabis effectively reduces symptoms of anxiety and depression.  The Drug Enforcement Agency (DEA) proposed increases in cannabis and psychedelic drug production for research purposes. The objective is to develop FDA approved treatments for several psycho-active plant materials currently classified as Schedule I controlled substances. Research on mixing psychoactive elements is critical for understanding how plant medicine can be optimized to treat mental disorders and additions. These key studies, increased access to federal funding, and the DEA’s proposal signify a turning point in support for research on cannabis and psychedelic treatments for mood disorders.

 

Sources: Johns Hopkins University MedicineMarijuana MomentJHU research study on psilocybin reducing anxiety

 

 

About the Author
  • Kerry Charron writes about medical cannabis research. She has experience working in a Florida cultivation center and has participated in advocacy efforts for medical cannabis.
You May Also Like
DEC 23, 2021
Immunology
Double Whammy Cytokine Hit Stops Transplant Side Effects
DEC 23, 2021
Double Whammy Cytokine Hit Stops Transplant Side Effects
  Patients who receive bone marrow or stem cell transplants are offered the gift of a new lease of life. However, s ...
DEC 22, 2021
Microbiology
Some Gut Bacteria Produce Toxic Chemicals That Can Damage the Brain
DEC 22, 2021
Some Gut Bacteria Produce Toxic Chemicals That Can Damage the Brain
Gut bacteria perform some essential functions. They help us digest certain foods and absorb nutrients. The community of ...
DEC 23, 2021
Cannabis Sciences
Acute Intoxication Effects of Legal-Market High-Potency THC-Enriched vs. CBD-Enriched Cannabis Concentrates
DEC 23, 2021
Acute Intoxication Effects of Legal-Market High-Potency THC-Enriched vs. CBD-Enriched Cannabis Concentrates
Researchers from Colorado State University and the University of Colorado Boulder have just released the first study to ...
DEC 22, 2021
Coronavirus
Which COVID vaccine and booster are right for me?
DEC 22, 2021
Which COVID vaccine and booster are right for me?
The 2-year anniversary of the COVID-19 pandemic, which began in December 2019, recently passed. It would not be overstat ...
DEC 26, 2021
Microbiology
To Understand the Gut Microbiome, Researchers Create New Method to ID Strains
DEC 26, 2021
To Understand the Gut Microbiome, Researchers Create New Method to ID Strains
We've long known that there are bacteria in the human gut; some can be dangerous if they are ingested. But genetic and c ...
JAN 05, 2022
Clinical & Molecular DX
Labroots 2021 Clinical Research & Diagnostics Virtual Event's Winning Poster
JAN 05, 2022
Labroots 2021 Clinical Research & Diagnostics Virtual Event's Winning Poster
The SARS-CoV-2 virus that emerged in December 2019 causes the disease COVID-19, a pandemic that has killed over 5 millio ...
Loading Comments...